Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644492 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL8592479 | 0.88 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL9795474 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL944313 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL29374052 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL207554 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL2001200 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 | |
| SCHEMBL437747 | 0.80 | TSHR (0.47) | ALDH1A1CYP3A4TDP1ALOX15HPGD | |
| SCHEMBL29516244 | 0.80 | TSHR (0.47) | ALDH1A1CYP3A4TDP1ALOX15HPGD | |
| SCHEMBL8675112 | 0.80 | ACHE (0.37) | ALDH1A1CYP3A4TDP1ALOX15ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | claimed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | claimed |
| CN-119080660-A | Thiosemicarbazide menthyl formate compound, preparation method and application thereof | 南京林业大学 | 2024-12-06 | — | — | CN | claimed |
| CN-114516848-B | Preparation method of polycarbonate high-temperature degradation resistant agent and polycarbonate composition | 万华化学集团股份有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117247409-A | 3-thio/seleno-phosphorylated imidazole derivative and synthetic method and application thereof | 曲阜师范大学 | 2023-12-19 | — | — | CN | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-9340518-B2 | Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-17 | — | — | US | claimed |
| CN-103864655-B | A kind of synthetic method of dehydrogenation abietyl thiourea derivative | GUANGXI UNIVERSITY (CN) | 2015-12-30 | — | — | CN | claimed |
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2015-07-23 | — | — | US | claimed |
| EP-2885266-A1 | PROCESS FOR THE PREPARATION OF!(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-!(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | Actelion Pharmaceuticals Ltd. (CH) | 2015-06-24 | — | — | EP | claimed |
| CN-104540800-A | Process for the preparation of (2Z,5Z)-5-(3-chloro-4- ((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | ACTELION PHARMACEUTICALS LTD | 2015-04-22 | — | — | CN | claimed |
| CN-103864655-A | Synthetic method of dehydroabietic acid group thiourea derivative | UNIV GUANGXI | 2014-06-18 | — | — | CN | claimed |
| WO-2014027330-A1 | PROCESS FOR THE PREPARATION OF|(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-|(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-02-20 | — | — | WO | claimed |
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20060241178-A1 | Compositions and methods for treating lung cancer | IMMUNEGUARD LLC (US) | 2006-10-26 | — | — | US | claimed |
| WO-2004060365-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | AMERICAN HEALTH FOUNDATION (US) | 2004-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | IL15, IL15RA, IL5 | ALDH1A1 428/4885CYP3A4 76/4885TDP1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.